SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...
Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...
The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results